DDO-2213

Customer Review

Based on 1 Customer Validation

DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research.

For research use only. We do not sell to patients.

  • Purity: 98.84%
  • CAS No.: 2378768-36-4
  • Formula: C24H27ClFN7O
  • Molecular Weight:483.97
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00